周六报道，Cogent Biosciences在SUMMIT NonAdvSM研究中强调Bezuclastini对肥大细胞负担客观指标的快速、深入、持续改善

2025-12-08 17:06

Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline --
Bezuclastinib demonstrates that reducing objective measures of disease, including serum tryptase, correlates with improvement in symptom severity; the first time this has been shown in NonAdvSM patients --
New 48-week data demonstrate a clear, continued deepening of symptomatic improvement over time --
Bezuclastinib demonstrated a favorable safety and tolerability profile supporting chronic use --
Granted Breakthrough Therapy Designation for bezuclastinib in October 2025; New Drug Application (NDA) on track for submission in December 2025 --